𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate

✍ Scribed by Kamal K. Midha; John W. Hubbard; Stephen R. Marder; Edward M. Hawes; Theodore Putten; Gordon McKay; Phillip R. A. May


Publisher
Springer
Year
1987
Tongue
English
Weight
551 KB
Volume
93
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis


Highly sensitive radioimmunoassays were applied to study the sulfoxidation of fluphenazine in 30 schizophrenic patients maintained on either 5 mg or 25 mg fluphenazine decanoate by intramuscular injection every 14 days over a period of 6 months. The presence of the sulfoxide metabolite was detected in all but one of the patients, such that 97% of the 340 plasma samples analysed contained the metabolite. Interpatient variations in plasma levels of fluphenazine, fluphenazine sulfoxide, and in drug to metabolite plasma level ratios were several fold higher than the corresponding intrapatient variations at both dosages. There were statistically significant tendencies for mean plasma fluphenazine levels to rise and mean plasma sulfoxide levels to fall over the 6-month period of study among patients on the high dose, consistent with our previously reported observation that it takes 3-6 months to establish a steady state of fluphenazine with this dosage regimen. By contrast, there were no statistically significant changes in mean plasma levels of either fluphenazine or its sulfoxide in patients on the low dose. Nevertheless, there was a significant rise in fluphenazine to fluphenazine sulfoxide mean plasma level ratios in both dosage groups. It is difficult to assess the significance of the changes in the drug to metabolite ratios with time, since there are no kinetic data on the phase II metabolism (conjugation) of fluphenazine or fluphenazine sulfoxide. This study shows that sulfoxidation is an important major pathway in the metabolism of intramuscularly-administered fluphenazine, and implies that metabolic sites other than gut wall are also involved in the process.


πŸ“œ SIMILAR VOLUMES


Fluphenazine plasma levels in patients r
✍ Stephen R. Marder; Edward M. Hawes; Theodore Putten; John W. Hubbard; Gordon McK πŸ“‚ Article πŸ“… 1986 πŸ› Springer 🌐 English βš– 487 KB

Plasma fluphenazine concentrations (FLU) were measured in 45 patients with schizophrenic disorders who participated in a double-blind comparison of 5 and 25 mg fluphenazine decanoate (FD). The rise in plasma level of FLU 24 h after a "test dose" was significantly correlated with steady state FLU con

Early unwanted effects of fluphenazine e
✍ A. C. Altamura; S. H. Curry; S. Montgomery; D. H. Wiles πŸ“‚ Article πŸ“… 1985 πŸ› Springer 🌐 English βš– 381 KB

Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary movement

Effects of alcohol on serum fluphenazine
✍ S. D. Soni; J. S. Bamrah; J. Krska πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 493 KB

Seven chronic schizophrenic patients, stable for over 12 months on maintenance fluphenazine decanoate, were administered 40 g of alcohol orally soon after their regular injection. Blood samples for estimation of serum neuroleptic and prolactin levels were collected at various intervals over a 12 h p

Serum and cerebrospinal fluid levels of
✍ Ranan RimΓ³n; Reima Kampman; Raili Laru-Sompa; D. H. Wiles πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 389 KB

Serum and cerebrospinal fluid (CSF) concentrations of fluphenazine (FPZ) were measured during nine weeks of FPZ medication in 28 patients with acute symptoms of schizophrenia. A significant correlation was found between the serum and CSF FPZ values (r = 0.70, p < 0-001) throughout the entire study.